<DOC>
	<DOCNO>NCT00540943</DOCNO>
	<brief_summary>Subjects enter cohort 3 dose escalation phase maximum tolerate dose determine . 18 additional patient recruit maximum tolerate dose ( MTD ) determine disease assessment .</brief_summary>
	<brief_title>Study Pazopanib , Irinotecan Cetuximab Combination Treat 2nd Line Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion criterion : Male female least 18 year age . Willing able sign write informed consent . Is either affiliated beneficiary social security category Histologically cytologically confirm diagnosis colorectal cancer . Subjects metastatic disease refractory relapse follow prior treatment . Documented disease progression prior treatment 5FU , oxaliplatin irinotecan containing regimen . Complete recovery surgical radiotherapy procedure . Eastern Cooperative Oncology Group performance status 0 1 , Karnofsky score ≥ 70 % . Able swallow retain oral medication . Adequate bone marrow function ( absolute neutrophil count great equal 1,500/mm3 , platelet count great equal 100,000/mm3 , hemoglobin level great equal 10g/dL ) . Adequate renal function determine creatinine clearance great 50 mL/minute calculate CockcroftGault Formula . Measured creatinine clearance great equal 50 mL/minute 24 hour urine collection acceptable lieu calculate value . Urine Protein Creatinine ( UPC ) Ratio ≤ 1 assessed random spot urine sample . Adequate hepatic function determine total bilirubin within normal range aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) less equal 2.5 time upper limit normal . Prothrombin time ( PT ) , international normalize ratio ( INR ) , partial thromboplastin time ( PTT ) less equal 1.2 time ULN . A female subject eligible enter participate study : ·Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include woman : Has hysterectomy , Has bilateral oophorectomy ( ovariectomy ) , Has bilateral tubal ligation , Is postmenopausal ( demonstrate total cessation menses great equal 1 year ) . Childbearing potential , negative serum pregnancy test screening , agree one following : An intrauterine device document failure rate le 1 % per year . Vasectomized partner sterile prior subject 's entry sole sexual partner woman . Complete abstinence sexual intercourse 14 day exposure investigation product , throughout clinical trial , least 21 day last dose investigational product . Double barrier contraception define condom spermicidal jelly , foam , suppository , film ; OR diaphragm spermicide ; OR male condom diaphragm . A male patient female partner childbearing potential eligible enter participate study use barrier method contraception abstinence study . Predicted life expectancy least 12 week . Able understand comply protocol requirement instruction intend complete study plan . Exclusion criterion : Has participate study use investigational drug previous 28 day . Has major surgery , chemotherapy , investigational agent , radiotherapy within last 28 day and/or recover prior therapy . Any history grade III toxicity relate prior treatment anti VEGF compound grade 3 hypertension subsequently control antihypertensive agent . Has receive prior treatment pazopanib / investigational antiangiogenic compound cetuximab . Prior treatment Avastin permit . Known contraindication use irinotecan cetuximab . Unable tolerate 180mg/m2 irinotecan every two week previous treatment . Is unable discontinue prohibit medication , stipulate protocol 14 day prior Visit 1 duration study Has receive Amiodarone arrythmias within last 6 month prior Visit 1 Has know allergy penicillin . Women pregnant lactating . Poorly control hypertension ( systolic blood pressure [ SBP ] 140 mmHg high , diastolic blood pressure [ DBP ] 90 mmHg high ) . Initiation adjustment blood pressure medication permit prior study entry provide subject 2 consecutive blood pressure read less 140/90 mmHg , separate minimum 24 hour . These reading need collect prior first dose . Corrected QT ( QTc ) prolongation define QTc interval great equal 480 msec prior history cardiovascular disease , arrhythmia , significant ECG abnormality . Has Class III IV heart failure define New York Heart Association functional classification system . Arterial thrombus , myocardial infarction , admission unstable angina , uncontrolled symptomatic arrhythmia , cardiac angioplasty , stenting within last 6 month . Any history cerebrovascular accident ( CVA ) , pulmonary embolism within last 6 month . History untreated deep venous thrombosis ( DVT ) within past 6 month ( e.g . calf vein thrombosis ) . Note : Patients recent DVT treat therapeutic anticoagulant agent ( exclude therapeutic warfarin ) least 6 week eligible . Current use therapeutic warfarin . NOTE : Low molecular weight heparin prophylactic lowdose warfarin ( 1mg per day ) permit . PT/PTT INR must within 1.2 time upper limit normal . Known history leptomeningeal brain metastasis . NOTE : Computed tomography magnetic resonance imaging ( MRI ) scan require rule central nervous system metastases unless subject exhibit neurologic sign symptom . If , however , CT MRI scan perform document central nervous system disease , subject ineligible , regardless whether neurologic sign symptom present . Any serious and/or unstable preexist medical , psychiatric , condition ( include laboratory abnormality ) could interfere subject safety obtain informed consent . History malabsorption syndrome , disease significantly affect gastrointestinal function major resection stomach small bowel could affect absorption , distribution , metabolism , excretion study drug . History unresolved bowel obstruction diarrhea . The subject know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , irinotecan , cetuximab , unless enrolment approve GSK Medical Monitor follow discussion Investigator . Psychological , familial , sociological , geographical condition permit compliance protocol . Is specifically prohibit medication require medication treatment pazopanib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>irinotecan ,</keyword>
	<keyword>pazopanib ,</keyword>
	<keyword>Colorectal cancer ,</keyword>
</DOC>